A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease

This study has been completed.
Sponsor:
Information provided by:
Genzyme, a Sanofi Company
ClinicalTrials.gov Identifier:
NCT00158600
First received: September 8, 2005
Last updated: June 24, 2010
Last verified: June 2010
Results First Received: June 24, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Pompe Disease (Late-onset)
Glycogen Storage Disease Type II (GSD-II)
Acid Maltase Deficiency Disease
Glycogenosis 2
Interventions: Biological: alglucosidase alfa
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
One hundred patients screened and 90 enrolled.

Reporting Groups
  Description
Alglucosidase Alfa Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks.
Placebo Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks.

Participant Flow:   Overall Study
    Alglucosidase Alfa     Placebo  
STARTED     60     30  
COMPLETED     55     26  
NOT COMPLETED     5     4  
unable to commit time to study                 0                 1  
Adverse Event                 2                 1  
Death                 1                 0  
Withdrawal by Subject                 2                 2  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Alglucosidase Alfa Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks.
Placebo Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks.
Total Total of all reporting groups

Baseline Measures
    Alglucosidase Alfa     Placebo     Total  
Number of Participants  
[units: participants]
  60     30     90  
Age [1]
[units: years]
Mean ± Standard Deviation
  45.3  ± 12.37     42.6  ± 11.63     44.4  ± 12.14  
Gender  
[units: participants]
     
Female     26     19     45  
Male     34     11     45  
Race/Ethnicity, Customized  
[units: participants]
     
Hispanic     1     1     2  
Asian     1     1     2  
Black or African American     0     0     0  
White     57     27     84  
Unknown or not reported     1     1     2  
[1] Age at First Infusion



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Summary of Patients Reporting Treatment-Emergent Adverse Events   [ Time Frame: weeks 0-78 ]

2.  Primary:   Mean Distance Walked as Measured by Six-minute Walk Test (6MWT) at Weeks 0 and 78, and Mean Change From Baseline   [ Time Frame: weeks 0, 78 ]

3.  Primary:   Percent of Predicted Forced Vital Capacity (FVC)   [ Time Frame: weeks 0, 78 ]
  Hide Outcome Measure 3

Measure Type Primary
Measure Title Percent of Predicted Forced Vital Capacity (FVC)
Measure Description Forced vital capacity is a standard pulmonary function test used to quantify respiratory muscle weakness. Forced vital capacity (FVC) is the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted forced vital capacity is based on a formula using sex, age and height of a person, and is an estimate of healthy lung capacity. Percent of predicted FVC = (observed value)/(predicted value) * 100%.
Time Frame weeks 0, 78  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
ITT population. Last observation carried forward.

Reporting Groups
  Description
Alglucosidase Alfa Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks.
Placebo Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks.

Measured Values
    Alglucosidase Alfa     Placebo  
Number of Participants Analyzed  
[units: participants]
  60     30  
Percent of Predicted Forced Vital Capacity (FVC)  
[units: percent predicted FVC]
Mean ± Standard Deviation
   
Baseline (week 0)     55.43  ± 14.44     53.00  ± 15.66  
Week 78 (or last observation)     56.71  ± 16.30     50.70  ± 14.88  
Change at Week 78 from Baseline     1.25  ± 5.55     -2.30  ± 4.33  


Statistical Analysis 1 for Percent of Predicted Forced Vital Capacity (FVC)
Groups [1] All groups
Method [2] ANCOVA
P Value [3] 0.0055
Difference [4] 3.40
95% Confidence Interval ( 1.03 to 5.77 )
[1] Additional details about the analysis, such as null hypothesis and power calculation:
  The difference between alglucosidase alfa and placebo treatment groups in change in % predicted FVC from baseline to last observation was estimated by ANCOVA after adjusting for baseline value and randomization strata.
[2] Other relevant method information, such as adjustments or degrees of freedom:
  No text entered.
[3] Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
  The threshold for determining statistical significance is 0.05. A fixed testing sequence procedure was used to preserve an overall error rate of 5% for the co-primary efficacy endpoints by linking the test of FVC to the result of 6MWT.
[4] Other relevant estimation information:
  No text entered.



4.  Primary:   Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Area Under the Curve (AUC)   [ Time Frame: weeks 0, 12 and 52 ]

5.  Primary:   Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Mean Maximum Plasma Concentration(Cmax)   [ Time Frame: weeks 0, 12, 52 ]

6.  Primary:   Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Mean Time to Maximum Plasma Concentration(Tmax)   [ Time Frame: weeks 0, 12, 52 ]

7.  Secondary:   Percent Predicted Proximal Muscle Strength of the Lower Limbs as Measured by Quantitative Muscle Testing (QMT)   [ Time Frame: weeks 0, 78 ]

8.  Secondary:   Health-related Quality of Life Survey Values Related to Physical Components as Measured by the Medical Outcomes Study (MOS) Short Form-36 Health Survey   [ Time Frame: weeks 0, 78 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information